Last reviewed · How we verify
FTC/TDF + EFV or LPV/R
This combination regimen suppresses HIV replication by blocking reverse transcriptase and protease enzymes essential for viral reproduction.
This combination regimen suppresses HIV replication by blocking reverse transcriptase and protease enzymes essential for viral reproduction. Used for HIV-1 infection treatment.
At a glance
| Generic name | FTC/TDF + EFV or LPV/R |
|---|---|
| Sponsor | French National Agency for Research on AIDS and Viral Hepatitis |
| Drug class | Antiretroviral combination therapy (NRTI + NNRTI or NRTI + PI) |
| Target | HIV reverse transcriptase, HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
FTC/TDF are nucleoside reverse transcriptase inhibitors (NRTIs) that block the enzyme responsible for converting HIV RNA into DNA. EFV is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works through a different mechanism on the same enzyme, while LPV/R is a protease inhibitor that prevents viral maturation. The combination targets multiple steps of the HIV replication cycle to achieve potent viral suppression.
Approved indications
- HIV-1 infection treatment
Common side effects
- Nausea
- Diarrhea
- Headache
- Rash
- Lipid abnormalities
- Hepatotoxicity
- Renal dysfunction (TDF-related)
Key clinical trials
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (PHASE3)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
- Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (PHASE3)
- Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF (PHASE3)
- Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years (PHASE3)
- Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC (PHASE3)
- Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: